The FDA has approved Sarclisa (isatuximab) as a first-line therapy for blood cancer multiple myeloma as a combination regimen ...

In addition to other MM indications, Isatuximab's anti-CD38 competitor on the US market, daratumumab (Darzalex — Johnson & Johnson), also carries a first-line indication for transplant-ineligible MM ...

Isatuximab (Sarclisa) with bortezomib, lenalidomide, and dexamethasone (VRd) is now an approved option for adults who cannot ...

The US Food and Drug Administration (FDA) has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first line treatment option for adult patients ...

The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who ...

During a Case-Based Roundtable® event, Andrzej Jakubowiak, MD, PhD, discussed 2 recent trials in multiple myeloma for ...

The Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc) with Velcade (bortezomib), Revlimid ...

Sanofi has claimed FDA approval for its anti-CD38 drug isatuximab as a third-line treatment for multiple myeloma, becoming the first direct rival to Johnson & Johnson’s big-selling Darzalex.

The Company’s pipeline of therapeutic candidates with standard-of-care agents include: About SARCLISASARCLISA (isatuximab-irfc) is a monoclonal antibody that binds to a specific epitope on the ...

The militant group targeted areas in Israel farther south than most of its previous attacks, reinforcing fears of broader regional conflict. For Middle Eastern Foes, Diplomacy Takes a Back Seat to ...

† Median OS not reached at 21 months for eight patients with primary PCL. CE: Cyclophosphamide, etoposide; dex: Dexamethasone; M-80: Intermediate-dose melphalan, dexamethasone; MP: Melphalan ...

The approval is supported by data from the phase 3 IMROZ study which demonstrated superior progression-free survival with ...